Accelerate to discover

Homepage>Discover>Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Back to filter

Oct 30, 2018

Dr. Schneider will show examples of data from customers who have incorporated pressure along with oxygen to recreate...

IncuCyte webinar: Latest developments in live-cell analysis & advanced cell models

Sep 26, 2018

Biomedical researchers are increasingly using advanced human cell models for translational biology and therapeutic...

IncuCyte webinar: Live-cell analysis of cell subsets and heterogeneity

Sep 3, 2018

Discover the new IncuCyte S3 cell-by-cell analysis software module. The innovative module allow label free analysis to...

Webinar Tuning Microenvironment to Control Cells for Improved Disease Modeling & Immunotherapy Work

Jul 16, 2018

The company producing Avatar, xCELL biosciences have organized a webinar about the tuning of microenvironment to...

Nov 19, 2018

How microCT can provide insight into dynamic disease processes webinar

Jun 19, 2018

Professor Vande Velde will describe how high-field MRI and low dose microCT complement each other; where microCT gives...

xCELLIgence webinar: label-free real-time cell analysis technology for Immuno-Oncology

Jun 5, 2018

Cancer immunotherapies harness and enhance the innate power of the immune system to eliminate cancer cells and have...

Photoacoustic Imaging of placental oxygenation

May 16, 2018

Watch the new webinar about photoacoustick imaging presented by Dr. Liliya M. Yamaleyeva, Assistant Professor in the...

Nov 19, 2018

BioFlux webinar: Introducing new plates and capabilities of BioFlux microfluidic system

May 13, 2018

BioFlux biofilm assays can now be performed on the popular catheter material polydimethylsiloxane (PDMS). Silicone...

Show all topics (10)

Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Oct 13, 2016

Nabil Ahmed, M.D., M.P.H. Associate Professor of Pediatrics, Baylor College of Medicine (USA).

Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors. We have used the xCELLigence Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including extracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.

Register now

Webinar

Related technologies: Real-time, label free cell analysis

Get more info